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ABSTRACT: Classification of rare missense substitutions
observed during genetic testing for patient management is
a considerable problem in clinical genetics. The Bayesian
integrated evaluation of unclassified variants is a solu-
tion originally developed for BRCA1/2. Here, we take a
step toward an analogous system for the mismatch repair
(MMR) genes (MLH1, MSH2, MSH6, and PMS2) that
confer colon cancer susceptibility in Lynch syndrome by
calibrating in silico tools to estimate prior probabilities of
pathogenicity for MMR gene missense substitutions. A
qualitative five-class classification system was developed
and applied to 143MMRmissense variants. This identified
74 missense substitutions suitable for calibration. These
substitutions were scored using six different in silico tools
(Align-Grantham Variation Grantham Deviation, multi-
variate analysis of protein polymorphisms [MAPP], Mut-
Pred, PolyPhen-2.1, Sorting Intolerant From Tolerant,
and Xvar), using curated MMR multiple sequence align-
ments where possible. The output from each tool was cal-
ibrated by regression against the classifications of the 74
missense substitutions; these calibrated outputs are inter-
pretable as prior probabilities of pathogenicity. MAPP was
the most accurate tool and MAPP + PolyPhen-2.1 pro-
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vided the best-combined model (R2 = 0.62 and area under
receiver operating characteristic = 0.93). The MAPP +
PolyPhen-2.1 output is sufficiently predictive to feed as
a continuous variable into the quantitative Bayesian inte-
grated evaluation for clinical classification of MMR gene
missense substitutions.
Hum Mutat 34:255–265, 2013. C© 2012 Wiley Periodicals, Inc.
KEY WORDS: mismatch repair; in silico; missense substi-
tutions; probability of pathogenicity
Introduction
Missense variants that cause a single amino acid substitution in
a protein sequence may or may not lead to altered protein func-
tion [Tavtigian et al., 2008c]. Many germline missense variants have
unclear functional and medical consequences and cannot be eas-
ily classified as either pathogenic or neutral before they have been
subjected to a detailed analysis. These variants of unknown clinical
significance cannot be used to guide patient management, and are a
source of anxiety for families [O’Neill et al., 2009]. Accurately plac-
ing them in a spectrum from neutral to clearly pathogenic through
the development of robust classification systems would allow re-
sources for screening, prevention, and treatment to be focused on
individuals truly at elevated genetic risk and provide reassurance
to those who are not at risk [Hicks et al., 2011; Miller et al., 2011;
Tavtigian et al., 2008c].
The most common form of hereditary colorectal cancer (CRC)
is Lynch syndrome (LS), which accounts for about 3% of all CRC
[Lynch et al., 2009]. LS results from defects in DNA mismatch
repair due to the inherited mutations in one of four mismatch
C© 2012 WILEY PERIODICALS, INC.
repair (MMR) genes MLH1 (MIM# 120436), MSH2 (MIM#
609389), MSH6 (MIM# 600678), and PMS2 (MIM# 600259) [Viel
et al., 1998; Wang et al., 1999]. Genetic testing for these four genes
is routinely performed. Between 20% and 30% of genetic variants
identified are missense variants, almost all of which are considered
of unknown clinical significance [Woods et al., 2007].
A five-tiered classification system, with recommendations for
clinical management of variants, was proposed by the IARC Work-
ing Group onUnclassified Genetic Variants, and is now under study
in several areas of clinical cancer genetics. When possible, each class
is associated with a probability that a variant is pathogenic derived
from statistical studies [Plon et al., 2008] that incorporate data from
various independent sources important to disease pathology. These
include clinicopathologic and epidemiological studies, but also in
vivo or in vitro functional assays, and computational (in silico)
analyses [Couch et al., 2008; Tavtigian et al., 2008b].
Strategies to integrate these methods have been a topic of sig-
nificant activity for researchers and clinicians working with MMR
and other cancer susceptibility genes [Arnold et al., 2009; Barnetson
et al., 2008; Easton et al., 2007;Goldgar et al., 2004;Miller et al., 2011;
Pastrello et al., 2011]. An increasingly well-developed method for
classifying variants (initially BRCA1 [MIM# 113705] and BRCA2
[MIM# 600185] variants) integrates different lines of genetic ev-
idence using Bayesian analysis [Easton et al., 2007; Goldgar et al.,
2004]: each variant starts with a “prior probability” of pathogenicity
based on in silico algorithm outputs, ultimately calibrated against a
reference set of variants that have been classifiedwith confidence us-
ing other types of data [Easton et al., 2007; Tavtigian et al., 2008a];
a “posterior probability” of pathogenicity is derived by updating
the prior probability with likelihood ratios (LR) or odds ratios for
pathogenicity determined from statistical analyses of observational
data such as segregation of the variant in families, pathological char-
acteristics, and in vitro studies.
A wide variety of in silico tools using various implementations
and combinations of features have now been developed [Tavtigian
et al., 2008c; Thusberg et al., 2011]. These in silico tools are gener-
ally based on: (1) analyses of sequence conservation at the position
of a missense substitution, which is measured from a protein mul-
tiple sequence alignment, (2) severity of a missense substitution
with respect to the observed range of variation at its position in
an alignment, and/or (3) structural features of the wild-type and
variant proteins. This study focuses on comparing the accuracies
and calibrating the outputs of in silico tools forMMRmissense sub-
stitution analysis. We report (1) a list of 74 qualitatively classified
MMR variants used in the calibration, (2) the creation of curated
protein multiple sequence alignments for the four MMR genes as-
sociated with LS, (3) comparison of six in silico tools for predicting
the pathogenicity of the list of variants, (4) comparison of pair-
wise combinations of these in silico tools, and (5) calibration of the
output, expressed as a continuous variable, of the best paired com-
bination in describing probability in favor of pathogenicity. This
output variable can be used now as a tool for classification, feeding
into the quantitative integrated evaluation of MMR gene missense
substitutions (see the accompanying paper [Thompson et al., in
press]).
Methods and Materials
Development of the Qualitative Classifier
An existing qualitative missense classifier originally developed
for research classification of Colon Cancer Family Registry (CCFR)
MMR gene variants [Thompson et al., 2012] was further devel-
oped with the coauthors, following suggestions from the InSiGHT
Mutation Interpretation Committee. The classifier presents a five-
class system as described for quantitative assessment of variant
pathogenicity in [Plon et al., 2008]. However, instead of mathe-
matically derived probabilities of pathogenicity, the classes reflect
consensus opinion that a set of qualitative data correspond to a
≥99%, ≥95%, ≤5%, or ≤0.1% probability of pathogenicity. Two
general types of data were combined: (1) association of the variant
with clinical cases of LS cancers, such as segregation with disease
in families, microsatellite instability-high (MSI-H) or loss of the
appropriate protein by immunohistochemistry (IHC) in tumors of
variant carriers; and (2) association of the variant with decreased
function in an in vitro assay. The criteria used to classify the vari-
ants are shown in Table 1. Importantly, the standardized qualitative
classifier excluded data from in silico tools.
Generation of the List of Qualitatively Classified Missense
Substitutions
An initial list of 143 MMR missense variants considered (likely)
pathogenic or neutral was compiled from five sources for stan-
dardized classification using the qualitative criteria (Table 1). These
sources were: a population-based study by Barnetson et al. (2008),
two studies of in silicomethods by Chan et al. (2007) and Chao et al.
(2008), variants identified by the Australasian CCFR population
and clinic-based recruitment arms [Arnold et al., 2009], common
missense substitutions drawn from dbSNP, (http://www.ncbi.nlm
.nih.gov/sites/entrez?db=snp). All the MMR variants assessed
(classes 1–5) have been submitted to the InSiGHT locus-specific
database (www.insight-group.org). Standardized classification used
mostly information from the literature/databases, supplemented
with someunpublished data on tumor characteristics collected from
the clinicians listed in the acknowledgments. None of these sources
reported using tumor prescreening criteria; overall only 56% of
these variants were associated with MSI-H tumors and only 41%
showed loss of IHC staining.
The 143 missense substitutions were classified independently by
two investigators (BAT and MSG), and discrepancies resolved by
consensus among four investigators (BAT, MSG, ABS, and SVT).
Variants with reported evidence of a splice defect were excluded
from further analysis to prevent the possibility of pathogenicity
actually attributable to splice effects from confounding analyses
of pathogenicity attributable to missense dysfunction. Calibration
used all truemissense variants that were ultimately classified as class
1, 2, 4, or 5 (but not class 3 variants).
Preparation of Protein Multiple Sequence Alignments
We constructed MLH1, MSH2, MSH6, and PMS2 protein mul-
tiple sequence alignments over a fixed phylogeny of species: hu-
man, Cercopithecidae (Macaca mulatta or Chlorocebus aethiops),
Glires (Mus musculus), Laurasiatheria (Bos taurus or Canis lupus),
Marsupialia (Monodelphis domestica), Aves (Gallus gallus), Am-
phibia (Xenopus laevis or Xenopus tropicalis), Teleostei (Danio re-
rio), Agnatha (Petromyzon marinus), Urochordata (Ciona intesti-
nalis), Cephalochordata (Branchiostoma floridae), Echinodermata
(Strongylocentrotus purpuratus), Cnidaria (Nematostella vectensis),
and Placozoa (Trichoplax adhearens). Individual sequences were
curated by hand, and in areas where exon predictions or splice
junction predictions were unclear, peptide sequences were re-
placed with “X,” rather than “-” to allow distinction between
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Table 1. Missense Classification Criteria
Class Criteria used for qualitative classification
Class 5—Pathogenic All of the following characteristics:
– deficient protein function in in vitro/ex vivo functional assays in mammalian system (cannot be in yeast only)
– cosegregation with disease in at least one AMS family with ≥4 affected carriers, or ≥2 familiesa with ≥3 affected nonproband carriers
– not present in the general population (>160 individuals = 320 alleles)
– MSI-H in ≥2 independent tumors with no contradictory IHC results or immunoloss of MMR protein(s) consistent with the variant
location in ≥2 independent tumors for MLH1 or ≥1 tumor for MSH2, MSH6, and PMS2
Class 4—Likely pathogenic Deficient protein function in one or more in vitro/ex vivo assays in any eukaryote, plus one of the following:
– cosegregation with disease in at least one AMS family with ≥3 affected carriers
– MSI-H in ≥2 independent tumors with no contradictory IHC results or immunoloss of MMR protein(s) consistent with the variant
location in ≥2 independent tumors for MLH1 or ≥1 tumor for MSH2, MSH6, and PMS2
Class 3—Uncertain Insufficient evidence to classify, that is, not class 1, 2, 4, or 5
Class 2—Likely not pathogenic Variants reported to occur in a specific ethnic group at frequency ≥1%, and that have not yet been excluded as known founder mutations
Or variants reported to occur in the general population at a frequency <1%, with normal protein function in in vitro/ex vivo functional
assays in any eukaryote and no aberrant splicing
Class 1—Not pathogenic Variants reported to occur in the general population at frequency ≥1%
Or present in the general population at frequency 0.1%– 1% and determined by large case-control studies to be associated with estimated
risk <1.5, with upper bound 95% CI <4
Note: These classification guidelines (froze in October 2011) are similar to criteria currently being developed and tested by the InSiGHT Mutation Interpretation Committee.
aThe families used in variant classification fulfilled the Amsterdam Criteria.
AMS, revised Amsterdam criteria [Vasen et al., 1999]; MSI-H, microsatellite instability-high.
ambiguous amino acids and true alignment gaps [Tavtigian et al.,
2008c]. Sequences were aligned using M-Coffee [Wallace et al.,
2006], followed by minor hand editing. The sequences and align-
ments satisfied three criteria: (1) the individual sequences are essen-
tially full-length and encode clear orthologs of the relevant human
protein, (2) the individual sequences are substantially free of cDNA
(or gene model) structural errors, and (3) the concatenated align-
ment of all four genes contains an average of at least three amino
acid substitutions per position and meets the missense substitution
analysis program Sorting Intolerant From Tolerant (SIFT) “me-
dian sequence conservation” criterion for confident prediction of
substitutions that should “affect protein function,” thus meeting
criteria of sufficient sequence diversity to grade missense substitu-
tions [Greenblatt et al., 2003;Ng andHenikoff, 2002; Tavtigian et al.,
2008c]. These alignments, or updated versions thereof, are available
at http://agvgd.iarc.fr/alignments.php.
Missense Substitution Scoring and Output Manipulation for
Regression Analyses
Missense substitutions were scored using six distinct in silico
tools.
(1) Align Grantham Variation Grantham Deviation (Align-
GVGD—http://agvgd.iarc.fr/) [Tavtigian et al., 2006, 2008a]
was run at three depths of sequence alignment: through
Strongylocentrotus (the shallowest alignment to reach the se-
quence diversity target of an average of three substitutions per
position), through Nematostella, and through Trichoplax. For
regressions, the standard output of seven grades was coded as 0
(for C0, the least likely functionally deleterious grade) through
6 (for C65, the most likely functionally deleterious grade). For
some regressions, C0 was split into two grades: GD = 0 (least
likely to be functionally deleterious) and GD > 0 (slightly more
likely to be functionally deleterious).
(2) Multivariate analysis of protein polymorphisms (MAPP—
http://mendel.stanford.edu/SidowLab/downloads/MAPP/)
[Stone and Sidow, 2005] was run at three depths of sequence
alignment: through Strongylocentrotus, through Nematostella,
and through Trichoplax. For regressions, we used the
MAPP score as a continuous variable and also used
ln(MAPP Score) as a continuous variable. MAPP-MMR
(http://mappmmr.blueankh.com/), which is a modification of
MAPP that focuses on the MMR genes MLH1 and MSH2, was
also run [Chao et al., 2008].
(3) PolyPhen-2.1 (http://genetics.bwh.harvard.edu/pph2/) [Adzh-
ubei et al., 2010] was used in two modes: (1) default mode
with native alignments, which is equivalent to the online
version, and (2) a custom mode in which the program was
retrained without MMR gene data. In the latter case, the na-
tive PolyPhen-2.1 MMR gene alignments were lightly edited to
remove 5′ or 3′ protein sequence segments that bore little or
no resemblance to the corresponding human gene, and internal
insertions that were likely to be consequences of exon boundary
prediction errors. From both modes, “HumVar” outputs were
used for statistical analyses. For regressions, “Class” (deleteri-
ous/neutral) was used as a binary predictor. “Benign/possible
damaging/probably damaging” was used as a trinary predictor
with benign set to 0, “probably damaging” set to 2, and the
value for “possible damaging” optimized; on this scale, the op-
timum value usually came out between 0.9 and 1.1. The output
variable “pph2_prob” was used as a continuous variable.
(4) MutPred (http://mutpred.mutdb.org/) [Li et al., 2009]was used
in two modes: (1) default mode with native alignments, which
is equivalent to the online version, and (2) a custom mode in
which the program was retrained without MMR gene data. For
regressions, we used the MutPred “RF score” with a threshold
of 0.5 as a binary variable, MutPred “RF score” as a continuous
variable, and ln(RF score) as a continuous variable.
(5) SIFT (http://sift.jcvi.org/) [Kumar et al., 2009;Ng andHenikoff,
2002] was used in two modes: (1) SIFT BLINK, which uses na-
tive SIFT alignments, and (2) with our curated alignments. In
the latter case, we checked the SIFT “median sequence con-
servation” score and found that only the complete alignments
(through Trichoplax) were diverse enough for confident pre-
diction of substitutions that should “affect protein function.”
Consequently, these are the alignments that we used with SIFT.
For regressions, we used the SIFT predictions of tolerated/affect
protein function as a binary predictor. We also used the SIFT
score and –log(SIFT + 0.01) as continuous variables.
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(6) Mutation Assessor (Xvar; http://mutationassessor.org/) [Reva
et al., 2011] was used in default online mode. Qualitative func-
tional impact (low/medium/high) was used as a trinary predic-
torwith low set to 0, “high” set to 2, and the value for “medium”
optimized; on this scale, the optimum value came out be-
tween 1.0 and 1.1. We used the output variable “Functional
Impact Score” and ln(Functional Impact Score) as continuous
variables.
Regression and Related Analyses
We performed three types of regression and related analyses: least
squares regression, ordinal logistic regression, and receiver oper-
ating characteristic (ROC) area analysis. Statistical analyses were
performed in STATA 11.0 (StataCorp, College Station, Texas, USA).
For least squares regressions, the qualitative class of each sequence
variant (pathogenic, likely pathogenic, likely not pathogenic, or not
pathogenic) was treated as the dependent variable and assigned the
minimumvalue for the threshold probability in favor of pathogenic-
ity from the corresponding quantitative classification system (0.99,
0.95, 0.05, or 0.001, respectively) [Plon et al., 2008]. The scores gen-
erated by the in silico tools for each sequence variant were treated as
independent variables. For analyses of the performance of individ-
ual in silico tools, we then performed least squares regressions on
logit(probability in favor of pathogenicity) (logit[Pr]) versus pro-
gram scores. For analyses of combined outputs from two in silico
tools, we performed bivariate least squares regressions on logit(Pr)
versus pairs of program scores. We note that using logit(Pr) as the
dependent variable constrains the resulting regression equations to
produce probabilities between 0.00 and 1.00, a feature normally
associated with logistic regression. For ordinal logistic regressions,
the qualitative class of each sequence variant was treated as the
dependent variable and assigned the ordering pathogenic > likely
pathogenic > likely not pathogenic > not pathogenic. Program scores
generated were treated as independent variables. For analyses of the
performance of individual in silico tools, we then performed ordinal
logistic regressions of qualitative class versus program scores. For
analyses of combined outputs from two in silico tools, we performed
bivariate ordinal logistic regressions on qualitative class versus pairs
of program scores. For ROC area under the curve (AUC) analyses,
we collapsed the qualitative classifications “pathogenic” and “likely
pathogenic” into“pathogenic” andcollapsed“likelynotpathogenic”
and “not pathogenic” into “not pathogenic.” For analyses of the per-
formance of individual in silico tools, this binary classification was
used as the reference variable and program scores were used as the
classification variable. For ROC area analyses of combined outputs
from two in silico tools, we used the regression intercept and co-
efficients calculated for a given pair of tools from the least squares
regression to calculate their combined score. The binary classifi-
cation was then used as the reference variable and the combined
program score was used as the classification variable.
A 10-fold cross-validation approach was used to estimate the
goodness of fit of the combined models, reported as adjusted R2
from bivariate least squares regressions. In each cross-validation
cycle, the 74 missense substitutions were randomly split into 10
approximately equal partitions, and each partition was then used
for testing the estimated linear regression equation learned from
the remaining nine partitions. After all 10 partitions were tested,
an adjusted R2 between the predicted and observed probabilities of
pathogenicity was calculated. This process was repeated indepen-
dently 1,000 times to obtain the adjusted R2 point estimates and
95% confidence intervals (CIs).
Results
Classification of 143 MMR Missense Variants Using a
Qualitative Classifier
Of the 143 variants analyzed, 12 were excluded because of the
evidence of aberrant splicing. Seventy-four (56.5%) of the remain-
ing missense substitutions could be classified as class 1, 2, 4, or 5,
which are clinically actionable. Of these, approximately 85% were
easily classified by consensus, and approximately 15% were con-
sidered potentially ambiguous, usually because of the existence of
discordant data combinations that were not explicitly included in
the criteria. The distribution of classifications was: class 1 (n = 20),
class 2 (n = 9), class 4 (n = 37), and class 5 (n = 8) (Table 2; Supp.
Table S1). The remaining 57 variants remained class 3, uncertain.
In silico Tools
In silico tools were applied as described in the section “Materials
and Methods.” In our initial analysis, MutPred, PolyPhen-2, and
Xvar were used as trained in their standard online form. These pro-
grams plus SIFT were used with their internally generated protein
alignments and all six programs were used under essentially default
conditions. All single programs performed fairly well. Most pro-
duced least squares regression adjusted R2 values >0.45 and P values
<10–10 (Table 3). The AUC of the ROC for all methods was >0.80
(data not shown). In these initial analyses, the two best performing
in silico tools from this analysis were MutPred and PolyPhen-2. We
explored whether evaluating output as a continuous rather than
a binary or trinary function would affect results. The continuous
variable approach yielded better correlation and lower P values for
the three programs where it was possible to compare continuous
output using least squares regression (Table 3) to binary output
using ordinal logistic regression (data not shown). The correlation
and P values differed little between continuous and trinary output
(likelydeleterious, intermediate, likelyneutral) for the twoprograms
where it was possible to compare least squares regression (Table 3)
to trinary output using ordinal logistic regression (data not shown).
Because the MutPred and PolyPhen-2.1 training data included
MMR gene missense substitutions that overlapped with our quali-
tatively classified set of substitutions, we conducted a second round
of analyses in whichMutPred and PolyPhen-2.1 were retrained with
datasets that excluded all MMR gene missense substitutions. The
multiple sequence alignments produced by PolyPhen-2.1 were also
lightly curated, and SIFT was rerun using the same set of highly cu-
rated alignments that were used with Align-GVGD and MAPP. All
six in silico tools output a continuous variable that was appropriate
for our analyses, so this second round of analyses focused on con-
tinuous variable outputs. Results, which we consider to have been
produced under analytically appropriate conditions for each of the
in silico tools tested, are summarized in Table 4. The performance
of SIFT improved using the curated alignments (least squares re-
gression R2 increased from 0.420 to 0.541), there was a very slight
degradation in the performance of PolyPhen-2.1 (R2 decreased from
0.591 to 0.575) and there was a more notable decrease in MutPred’s
performance (R2 decreased from 0.600 to 0.396). In this analysis,
the program rankings obtained after least squares regression and
after ordinal logistic regression were identical, and there was only
one difference in the ordering obtained from the ROC area anal-
ysis. The best result was obtained for MAPP, with R2 > 0.58 and
AUC > 0.92; these results were only very slightly stronger than those
obtained for PolyPhen-2.1 (Table 4). The distributions of the set
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Table 2. Qualitative Classification of 143 Missense Substitutions Evaluated for Use in Calibration of In Silico Tools
Class 1—not pathogenic (n = 20) Class 3—uncertain (cont.) Class 3—uncertain (cont.) Class 4—likely pathogenic (cont.)
MLH1 p.(Ile32Val) MLH1 p.(Glu89Gln) MSH2 p.(Pro349Arg) MLH1 p.(Leu749Pro)
MLH1 p.(Val213Met) MLH1 p.(Ser93Gly) MSH2 p.(Phe447Val) MLH1 p.(Arg755Ser)
MLH1 p.(Ile219Val) MLH1 p.(Thr117Arg) MSH2 p.(Gly548Asp) MSH2 p.(Val161Asp)
MLH1 p.(Ile219Leu) MLH1 p.(Lys134Asn) MSH2 p.(Asn596Ser) MSH2 p.(Gly162Arg)
MLH1 p.(Gln689Arg) MLH1 p.(Arg217Cys) MSH2 p.(His639Leu) MSH2 p.(Gly164Arg)
MLH1 p.(Val716Met) MLH1 p.(Asp304Gly) MSH2 p.(Ile704Val) MSH2 p.(Leu173Pro)
MLH1 p.(His718Tyr) MLH1 p.(Arg325Gln) MSH2 p.(Ala834Thr) MSH2 p.(Leu187Pro)
MSH2 p.(Asn127Ser) MLH1 p.(Lys443Gln) MSH2 p.(Asn835His) MSH2 p.(Cys333Tyr)
MSH2 p.(Gly322Asp) MLH1 p.(Thr452Ser) MSH2 p.(Leu911Arg) MSH2 p.(Asp603Asn)
MSH2 p.(Leu390Phe) MLH1 p.(Val506Ala) MSH2 p.(Val923Glu) MSH2 p.(Gly692Arg)
MSH2 p.(Ile735Val) MLH1 p.(Gly532Val) MSH6 p.(Pro623Ala) MSH2 p.(Cys697Arg)
MSH6 p.(Gly39Glu) MLH1 p.(Trp538Gly) MSH6 p.(Glu983Gln) MSH2 p.(Cys697Phe)
MSH6 p.(Leu396Val) MLH1 p.(Leu549Pro) PMS2 p.(Arg20Gln) MSH2 p.(Glu749Lys)
MSH6 p.(Val878Ala) MLH1 p.(Pro581Leu) PMS2 p.(Asn775Ser) MSH2 p.(Gly751Arg)
MSH6 p.(Ile886Val) MLH1 p.(Asp601Gly) PMS2 p.(Ser46Ile)Class 4—Likely pathogenic (n = 37)
PMS2 p.(Thr277Lys) MLH1 p.(Leu607His) Class 5—Pathogenic (n = 8)
PMS2 p.(Pro470Ser) MLH1 p.(Lys618Ala) MLH1 p.(Pro28Leu)
PMS2 p.(Thr485Lys) MLH1 p.(Lys618Thr) MLH1 p.(Asp63Glu) MLH1 p.(Met35Arg)
PMS2 p.(Thr597Ser) MLH1 p.(Tyr646Cys) MLH1 p.(Gly67Trp) MLH1 p.(Asn38His)
PMS2 p.(Met622Ile) MLH1 p.(Arg659Gln) MLH1 p.(Gly67Glu) MLH1 p.(Ser44Phe)
Class 2—Likely not pathogenic (n = 9) MLH1 p.(Leu729Val) MLH1 p.(Cys77Arg) MLH1 p.(Gly67Arg)
MLH1 p.(Asp737Val) MLH1 p.(Cys77Tyr) MLH1 p.(Thr117Met)
MLH1 p.(Val326Ala) MSH2 p.(Ala2Thr) MLH1 p.(Phe80Val) MLH1 p.(Leu622His)
MLH1 p.(Val384Asp) MSH2 p.(Val3Leu) MLH1 p.(Lys84Glu) MSH2 p.(Pro622Leu)
MLH1 p.(Ser406Asn) MSH2 p.(Phe19Leu) MLH1 p.(Ile107Arg) MSH2 p.(Ala636Pro)
MLH1 p.(Ile655Val) MSH2 p.(Thr33Pro) MLH1 p.(Leu155Arg) Splicing Defects (n = 12)
MLH1 p.(Lys751Arg) MSH2 p.(Leu93Phe) MLH1 p.(Val185Gly)
MLH1 p.(Asp41Gly)MSH2 p.(Asp167His) MSH2 p.(Arg96His) MLH1 p.(Gly244Asp)
MLH1 p.(Arg100Pro)MSH2 p.(Gln629Arg) MSH2 p.(Tyr103Cys) MLH1 p.(Ser247Pro)
MLH1 p.(Arg182Gly)MSH2 p.(Met688Ile) MSH2 p.(Arg106Lys) MLH1 p.(Leu550Pro)
MLH1 p.(Arg265Cys)MSH6 p.(Val509Ala) MSH2 p.(Val163Asp) MLH1 p.(Asn551Thr)
MSH2 p.(Leu175Pro) MLH1 p.(Leu559Arg) MLH1 p.(Ser295Asn)
Class 3—Uncertain (n = 57) MSH2 p.(Glu188Gln) MLH1 p.(Leu582Phe) MLH1 p.(His329Pro)
MLH1 p.(Arg18Cys) MSH2 p.(Lys246Gln) MLH1 p.(Ala589Asp) MLH1 p.(Arg659Leu)
MLH1 p.(Gly22Ala) MSH2 p.(Lys248Glu) MLH1 p.(Pro648Ser) MLH1 p.(Arg659Pro)
MLH1 p.(Glu23Lys) MSH2 p.(Leu330Pro) MLH1 p.(Pro648Leu) MLH1 p.(Glu663Asp)
MLH1 p.(Ala29Ser) MSH2 p.(Leu341Pro) MLH1 p.(Pro654Leu) MSH2 p.(Ala272Val)
MLH1 p.(Asn38Ser) MSH2 p.(Val342Ile) MLH1 p.(Arg687Trp) MSH2 p.(Ser554Gly)
MSH2 p.(Ser554Asn)
Note: Variant nomenclature was derived from the GenBank reference sequences NM_000249.3 forMLH1, NM_000251.1 forMSH2, NM_000179.2 forMSH6, and NM_000535.5
for PMS2. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, with the initiation
codon as codon 1.
Table 3. Least Squares Regression Results from Individual Analysis Programs Run under Essentially Default Conditions
Binary classification Trinary classification Continuous variable
Analysis program Adjusted R2 P value Adjusted R2 P value Adjusted R2 P value
MutPreda 0.550 2.39 × 10–14 N/A N/A 0.600 3.41 × 10–16
PolyPhen2.1a 0.464 1.45 × 10–11 0.577 2.60 × 10–15 0.591 7.60 × 10–16
MAPPb N/A N/A N/A N/A 0.586 1.15 × 10–15
Align-GVGDc N/A N/A N/A N/A 0.452 3.35 × 10–11
Xvara N/A N/A 0.465 1.39 × 10–11 0.449 4.01 × 10–11
SIFTa 0.356 1.19 × 10–8 N/A N/A 0.420 2.53 × 10–10
aOnline, default running conditions.
bHand-curated alignment through star anemone, using ln(MAPP score) as a continuous variable.
cHand-curated alignment through sea urchin, using the default 7 grades.
N/A, not applicable.
of 74 missense variants on the sigmoid curves generated from the
least squares regression equations for MAPP and PolyPhen-2.1 are
shown in Figure 1A and B.
Under the conditions used to compare these six in silico tools,
their outputs were highly correlated (Table 5). The strongest cor-
relation was between PolyPhen-2.1 and SIFT (R2 = 0.92). Seven of
15 pairs had R2 ≥ 0.80. The weakest correlation was between Align-
GVGDandMutPred (R2 = 0.61).Usingbivariate regressions,we then
explored the consequence of combining the output from each of the
three better performing in silico tools with the output of each of the
other tools. By the criterion that both programs make a significant
contribution to the least squares regression bivariate model, five
pairs of programs gave stronger results than either member of the
pair alone. In order of adjusted R2, these were: MAPP + PolyPhen-
2.1, Polyphen-2.1 + Align-GVGD, PolyPhen-2.1 + MutPred, SIFT +
Align-GVGD, and SIFT + MutPred (Table 6). With the addition of
the criteria that both programs also make a significant contribution
to the bivariate ordinal logistic regression and increase the ROC area
over that achieved by either program alone, only the combination
MAPP + PolyPhen-2.1 outperformed its individual components.
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Table 4. Results from Individual Analysis Programs Run Under Analytically Appropriate Conditions
Logit regression Ordered logistic regression
Analysis program Adjusted R2 P value Pseudo R2 P value ROC area
MAPPa 0.586 1.15 × 10–15 0.253 2.26 × 10–11 0.928
PolyPhen-2.1b 0.575 3.15 × 10–15 0.250 2.83 × 10–11 0.925
SIFTc 0.541 5.07 × 10–14 0.250 2.76 × 10–11 0.878
Align-GVGDd 0.505 7.73 × 10–13 0.222 2.61 × 10–10 0.912
Xvare 0.449 4.01 × 10–11 0.191 5.83 × 10–9 0.872
MutPredf 0.396 1.12 × 10–9 0.163 7.78 × 10–8 0.867
aHand-curated alignment through star anemone, using ln(MAPP score) as a continuous variable.
bTrained excluding MMR genes, with lightly curated PolyPhen-generated alignments, using “probability pph2” as a continuous variable.
cHand-curated alignment through Trichoplax, using –log(SIFT score +0.01) as a continuous variable.
dHand-curated alignment through sea urchin, using 8 grades.
eRun under default conditions using “Functional Impact Score” as a continuous variable.
fTrained excluding MMR genes, using the “probability of a deleterious substitution” as a continuous variable.
Backward selection arrived at the same result. Starting with all six
in silico tools in a single model, removing the tool that made the
weakest contribution to the combined model, and then repeating
the process with five-tool, four-tool, and three-tool models, the or-
der in which tools dropped out was: SIFT, Xvar, Align-GVGD, and
MutPred. There were no models combining three or more in silico
tools in which all of the tools made a significant contribution. The
order in which the in silico tools dropped out was the same under
least squares regression and ordinal logistic regression. Therefore,
MAPP + PolyPhen-2.1 appears to be the best combination. This pair
achieved an adjusted least squares regression R2 of 0.62 (bootstrap
95% CI 0.46–0.80) and an ordinal logistic regression pseudo R2 of
0.28 (bootstrap 95% CI 0.16–0.41). The ROC AUC (Fig. 1C) was
0.933 (95% CI 0.87–0.99). The lower bound of the 95% CIs for
adjusted R2, pseudo R2, and AUC includes the performance point
estimates from four of the individual algorithms and all of the pairs
tested, but provides evidence against the argument that the two
weaker in silico tools are actually equivalently effective predictors
under the conditions used. To assess whether we have overestimated
model performance, we used a cross-validation approach to reesti-
mate adjusted R2 for the bivariate least squares regression models.
The cross-validationR2 were only slightly decreased, by 0.03 to 0.04,
from the directly estimated R2 (Table 6).
The least squares regression equation determined for the combi-
nationMAPP +PolyPhen-2.1was: logit(Pr) = –9.20 + 2.27(ln[MAPP
score]) + 4.26(“pph2_prob” output from retrained PolyPhen-2.1).
The 95% CIs on the intercept, MAPP coefficient, and PolyPhen-
2.1 coefficient were (–11.61 to –6.79), (0.80–3.75), and (1.11–7.41),
respectively. Figure 1D shows the scatter plot of results compar-
ing qualitatively assigned probability in favor of pathogenicity ver-
sus probability of pathogenicity as a continuous variable calculated
from the MAPP + PolyPhen-2.1 output. Of the set of 74 variants,
there were six class 4/5 variants with <50% prior probability of
pathogenicity, and five class 1/2 variants with >50% probability of
pathogenicity. No major patterns were noted among the 11 dis-
cordant predictions; however, two of the MLH1 pathogenic vari-
ants that were predicted to have <50% likelihood of pathogenicity
were in adjacent codons within the interaction domain. In addition,
there was existing in vitro evidence suggesting partial loss of MMR
function or protein binding for three of the five variants considered
“likely not pathogenic” (see Fig. 1D and Supp. Table S1). These three
variants were classified on the basis of allele frequency in a control
population, overriding functional assay results as per criteria stated
in Table 1.
Results from the MAPP + PolyPhen-2.1 prior probability
database/calculator are available through: http://hci-lovd.hci.utah
.edu/. For the 57 variants that were assigned Class 3, 25% had in
silico scores predicting >90% probability of pathogenicity, and 30%
predicting >10% probability of pathogenicity (see Supp. Table S2).
Discussion
In several areas in cancer genetics, multiple data types are com-
bined to assess the effects of genetic variants. Quantifying data types
and applying integrated Bayesian analysis appears to be a robust ap-
proach to classifying variants [Arnold et al., 2009; Easton et al.,
2007; Goldgar et al., 2004; Miller et al., 2011]. An important princi-
ple of classification, using this method, is that at least two different
sources of data should be used for variant classification [Plon et al.,
2008]. One approach to calibration of the individual components
of the integrated evaluation of MMR gene unclassified missense
substitutions would be to begin from a large series of securely classi-
fied missense substitutions. Ideally, these would be classified on the
combined basis of segregation data (to show that the allele is asso-
ciated with the syndrome) and functional assay data (to show that
the identified variant, rather than a linked but unobserved variant,
damages protein function) as a gold standard. However, because
extensive segregation data on individual missense substitutions are
scarce and functional assay data are often conflicting, very fewMMR
missense substitutions can actually be classified on this basis.
As an alternative first step, in silico tools can provide prelimi-
nary evidence on the effects of all missense variants. To develop this
approach for clinical use in statistical variant classification mod-
els, we have qualitatively classified a set of MMR gene missense
substitutions that were not preselected for IHC, MSI, or other clin-
icopathologic features, and then used class 1, 2, 4, and 5 variants
to calibrate the output from a number of in silico missense substi-
tution analysis tools as a probability in favor of pathogenicity. The
performance of all classifiers that we tested was generally good, with
95% CIs overlapping considerably for many of them. Although we
rank our preferences for the various methods, our study solidifies
the concept that properly applied in silico methods carry sufficient
power to be used clinically inmodels for variant classification. As an
indication of the internal consistency of our study, it is encouraging
that MAPP performed best in all regression and AUC of the ROC
analyses, and that PolyPhen-2.1 functioned almost as well.
Three noteworthy factors emerged from our analyses of the indi-
vidual in silico tools:
(1) The importance of excluding MMR gene variants from a train-
ing set used to train the in silico tool. The generally accessible
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Figure 1. A: Distribution of the set of 74 class 1–2–4–5 missense variants on a sigmoid curve for MAPP outputs derived using the logit regression
calibration equation—Logit(Pr) = −10.84 + 3.99(ln[MAPP score]), where Pr is the probability in favor of pathogenicity. The classifications of the
variants are identified by colored symbols (defined in the legend). B: Sigmoid curve showing the outputs of the 74 missense variants from PolyPhen-
2.1 using the logit regression calibration equation—Logit(Pr) = −6.04 + 8.45(pph2_prob). The missense variants with the largest differences ()
in probability of pathogenicity derived from MAPP versus PolyPhen-2.1 are identified in (A) and (B): MLH1 V185G ( = 0.528), MLH1 V326A ( =
0.733),MLH1 L582F ( = 0.748),MLH1 H718Y ( = 0.719), andMSH6 V509A ( = 0.553). C: Receiver operating characteristic (ROC) curves for MAPP
and combined MAPP + PolyPhen-2.1 accuracy, using probabilities and scores associated with each program. D: Scatter diagram comparing the
qualitatively assigned probability in favor of pathogenicity (class 1—not pathogenic, class 2—likely not pathogenic, class 4—likely pathogenic,
and class 5—pathogenic) with the probability of pathogenicity as a continuous variable calculated from the MAPP + PolyPhen-2.1 outputs. The
pie graphs are proportional representations of overlapping variants in the four mismatch repair genes (MLH1—blue,MSH2—red,MSH6—green,
and PMS2—black). The variants with in silico scores predicting <0.40 probability of pathogenicity that were qualitatively classified as class 4 and
class 5 are identified, as were variants that had in silico scores predicting >0.60 probability of pathogenicity with qualitative classifications of class
1 and class 2.
Table 5. Pairwise Correlation Matrix
PP2.1a SIFT A-GVGDb Xvar MutPred
MAPP 0.86 0.89 0.82 0.78 0.69
PolyPhen-2.1 0.92 0.80 0.86 0.67
SIFT 0.79 0.84 0.67
Align-GVGD 0.73 0.61
Xvar 0.75
Computational tool use conditions are as in Table 4.
aPP2.1 is PolyPhen-2.1.
bA-GVGD is Align-GVGD.
online versions ofMutPred, PolyPhen-2, and Xvar were trained
using data sets that includedMMR variants. To eliminate over-
lap between training and calibration sets and thereby reduce
the possibility of overfitting during our calibration exercise, the
twomore promising methods (MutPred and PolyPhen-2) were
retrained by omitting all MMR variants from their training
set. This resulted in significant degradation of performance for
MutPred, but only a very small decrease for PolyPhen-2.1. This
result calls into question a number of missense substitution
in silico tool performance studies (e.g., Thusberg et al., 2011)
reported over the last several years, in which variants in the
gene of interest were part of the training set. Therefore, it is
very important that this process is repeated for genes included
in previous studies to investigate whether there is a similar
degradation in program performance.
(2) The performance of the in silico tools is sometimes influenced
by themultiple sequence alignmentwithwhich they are run. All
of the in silico tools except for Align-GVGDandMAPPhave in-
ternally generated libraries of alignments. SIFT is unique in that
it also gives users the option to supply their own alignment. In
agreement with previous observations [Chan et al., 2007; Hicks
et al., 2011], we found that SIFT performed markedly better
with our hand-curated alignments than with its native align-
ments. PolyPhen-2.1 was run using two sets of alignments:
native PolyPhen-2, and lightly hand-curated versions omit-
ting grossly discordant sequences in conserved areas that were
probably artifacts of either gene model assembly from genomic
sequence or the automated alignment generating programs.
Modest curation of the PolyPhen-2 alignment led to only mod-
est changes in the results. Align-GVGD and MAPP were run
with hand-curated alignments prepared at three different phy-
logenetic depths. Modest changes in depth of alignment pro-
duced only modest changes in performance.
(3) Using in silico tool output as a continuous variable. Although,
many methods generate data on a continuous scale, most al-
gorithms apply a binary “cutoff point” and report results as
likely pathogenic or likely not. The continuous output from
our analysis showed that the predictive value for many vari-
ants was well over 90% and for other variants was between
25% and 75%. This degree of variation would be diluted if the
output were categorized. We showed that considering data as a
continuous variable provides better correlation with classifica-
tion than does the binary output. There was no evidence for a
Table 6. Results from Regressions Using Pairs of Programs
Program combination Least squares regression Ordered logistic regression
















P value Model P value ROC aread
MAPP PolyPhen-2.1 0.620 0.585 0.003 0.009 4.67 × 10–16 0.2753 0.038 0.048 2.57 × 10–11 0.933
MAPP SIFT 0.595 0.553 0.002 0.116 4.30 × 10–15 0.2679 0.080 0.108 4.95 × 10–11
MAPP Align-GVGD 0.603 0.570 <0.001 0.051 2.23 × 10–15 0.2665 0.009 0.119 5.63 × 10–11
MAPP Xvar 0.595 0.562 <0.001 0.112 4.20 × 10–15 0.2622 0.001 0.194 8.19 × 10–11
MAPP MutPred 0.602 0.566 <0.001 0.056 2.37 × 10–15 0.2656 <0.001 0.122 6.07 × 10–11
PolyPhen-2.1 SIFT 0.578 0.537 0.009 0.226 1.91 × 10–14 0.2635 0.123 0.132 7.34 × 10–11
PolyPhen-2.1 Align-GVGD 0.599 0.561 <0.001 0.024 3.07 × 10–15 0.2686 0.006 0.073 4.66 × 10–11 0.922
PolyPhen-2.1 Xvar 0.571 0.534 <0.001 0.598 3.47 × 10–14 0.2515 0.002 0.610 2.12 × 10–10
PolyPhen-2.1 MutPred 0.598 0.564 <0.001 0.026 3.31 × 10–15 0.2674 <0.001 0.078 5.17 × 10–11 0.923
SIFT Align-GVGD 0.580 0.541 <0.001 0.007 1.53 × 10–14 0.2692 0.007 0.072 4.43 × 10–11 0.912
SIFT Xvar 0.544 0.505 <0.001 0.238 3.00 × 10–13 0.2529 0.002 0.496 1.87 × 10–10
SIFT MutPred 0.570 0.531 <0.001 0.018 3.62 × 10–14 0.2649 <0.001 0.103 6.45 × 10–11 0.914
aComputational tool operating conditions were as defined in Table 4.
bAdjusted R2 directly from least squares regression.
cAdjusted R2 directly from cross-validation.
dROC area calculated after application of the equation defined by the logit regression. Note that ROC area was only calculated for the combined computational tools where both
tools contributed P < 0.05 to the least squares regression (in bold).
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difference in the utility of using the output as a trinary variable,
but fitting trinary variables for each of the in silico tools would
involve considerable multiple testing and increase risk of over-
fitting.We encourage the use of continuous variable outputs for
all results included in classification tools, to avoid the artificial
dichotomy of binary categorization that may disregard useful
subtleties in data, particularly for variants that are difficult to
categorize using any individual tool. In the overall flow of the
Bayesian integrated evaluation, the only point where we abso-
lutely need to collapse from continuous variables to a limited
set of qualitative classes is at the very end, when the output
(posterior probability in favor of pathogenicity) is interpreted
through the clinical five-class system described by Plon et al.
(2008).
Many studies report the predicted effect of MMR gene missense
substitutions on protein function determined from in silico tools,
most commonly SIFT and PolyPhen. Those relevant to this study
are discussed below. Chao et al. (2008) classified a set of MMR
gene missense variants based on less rigorous clinical criteria than
those incorporated in our qualitative classifier, and then used these
classified variants to compare the accuracy of three in silico tools:
MAPP, PolyPhen, and SIFT. As in this study, MAPP was the best
performing in silico tool [for Chao et al., 2008]; however, it should
be noted that use of the multiple sequence alignments with MAPP
in the Chao et al. (2008) study was manipulated by varying the gap
weight threshold across the alignments. Nonetheless, we note that
the MAPP-MMR AUC of the ROC value reported by Chao et al.
(2008) (0.945) was very near our point estimate and well within
the 95% CI for our MAPP ROC value. Thus in a research area
not noted for between-study consistency, the close correspondence
between results obtained withMAPP in these two studies stands out
as a welcome exception. On the contrary, both SIFT and PolyPhen
performed somewhat better in our study than they had in Chao
et al. (2008). For SIFT, we attribute the difference to our use of
hand-curated alignments and use of the SIFT score as a continuous
variable rather than as a binary classifier. For PolyPhen, there have
been notable algorithm improvements in the intervening years, and
these may account for the difference.
Ali et al. (2012) have recently published on a consensus-based
predictor called PON-MMR that combines five in silico programs
to derive a probability that a missense substitution will show loss of
function in a functional assay. Although PON-MMR has a higher
sensitivity (0.97) compared with theMAPP + PolyPhen-2.1 (0.933),
we note some limitations of this study. Classification of the MMR
variant calibration set was based on functional data alone, and the
relationship between functional abrogation and pathogenicity as
defined by clinical phenotype was not calibrated. The probability
that a substitution will show dysfunction in a functional assay is a
proxy for, rather than a direct measure of, the probability in favor
of pathogenicity in humans. Furthermore, there is a risk that the
model is overfit because there was no clean separation between the
in silico program training sets and the sequence variant calibration
set. We have seen evidence that this can be very important in the
results of our own study. Additionally, the contribution of the in
silico programs to the PON-MMR output was not addressed, which
could also cause further overfitting. These concerns are explicitly
addressed in the model we present here.
Two studies, Barnetson et al. (2008) and Pastrello et al. (2011),
addressed classificationofMMRvariants by integrating in silico pre-
dictions with other lines of evidence. Barnetson et al. (2008) devised
an arbitrary scoring system for variant classification that included
SIFT and PolyPhen assessments as points of evidence, but there was
no attempt to calibrate the in silico predictions per se. Pastrello et al.
(2011) described a Bayesian approach to MMR missense variant
classification that included a LR for missense substitutions based on
in silico predictions using the tool Align-GVGD. However, the LRs
assigned for MMR substitutions were actually based on those de-
rived empirically for missense substitutions in BRCA1 and BRCA2
[Tavtigian et al., 2008a]. Because the LRs or probabilities associated
with the individual grades generated by Align-GVGDdepend on the
depth of alignment and because the program’s accuracy can degrade
badly if it is not used with carefully curated alignments [Hicks et al.,
2011; Tavtigian et al., 2008c], the approach taken by Pastrello et al.
(2011) was suboptimal.
Here, we have advanced the field by combining (1) a set of ref-
erence variants that have been classified using carefully considered
criteria vetted in the MMR variant community with (2) rigorously
controlled analytic conditions for computational methods. We an-
ticipate that a similar strategy applied to in vitro functional as-
says (MMR and other) would similarly advance the field of variant
classification. The probabilities in favor of pathogenicity that we
have derived can be used as a prior probability of pathogenicity
to feed into a multifactorial likelihood model for quantitative inte-
grated evaluation of unclassified variants. However, we note that the
clinical recommendations of the thresholds for “likely pathogenic”
and “likely not pathogenic” are posterior probabilities in favor of
pathogenicity of 0.95 and 0.05, respectively [Plon et al., 2008]. The
MAPP + PolyPhen-2.1 output is able to produce prior probabilities
that are more extreme than these thresholds. Because we view direct
classification on the basis of the prior probability alone as a misuse
of the Bayesian integrated evaluation model, we choose to truncate
the dynamic range of the prior probability database/calculator to a
maximumof 0.90 and aminimumof 0.10 so that additional sources
of information are required to reach posterior probabilities that alter
clinical management of patients with variants. The successful ap-
plication of this method for classification of MMR gene variants in
an integrated evaluation model that incorporates segregation and
tumor pathology information is described in the accompanying
manuscript humu-2012-0145.R1_001–010. Similarly, initial appli-
cation of our in silico tool to the 57 class 3 variants in our study
suggests that approximately 50% could be classified using Bayesian
integrated analysis with additional supporting information ofmod-
erate strength from only one other data source.
There are several caveats to our findings. Clear discordance be-
tween prior probabilities and qualitative classifications for a mi-
nority of variants indicates that the in silico modeling does not
adequately capture all alterations in protein function. In addition,
the in silico tools assessed do not account for missense substitutions
where the underlying sequence variant causes a splicing aberration.
Important statistical caveats to the calibration equation must also
be considered. First, the least squares regressions using logit(Pr) as
the dependent variable, which constrains the resulting probabilities
to fall between 0.00 and 1.00, assumes the probabilities assigned
to the groups of variants in each of the four qualitative categories
are reasonably accurate. The investigators who helped devise the
qualitative classification were explicitly aware of the quantitative
probability thresholds set for those categories in Plon et al. (2008)
and genuinely attempted to craft the qualitative categories to corre-
spond with the quantitative categories. But significant error, espe-
cially in the two extreme categories class 5 (pathogenic) and class 1
(not pathogenic), would alter the calibration. The main alternative
would have been to use the ordered logistic regressions to generate
the calibration, but two less obvious assumptions would have been
required here. The first is the proportional odds assumption that
underlies ordinal logistic regression, which is that the coefficients
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describing the relationship between the lowest versus all higher cat-
egories of the dependent variable are the same as those that describe
the relationship between the next lowest category and all higher
categories, and so on. The second is that converting the resulting
calibration from LRs to probabilities assumes an underlying overall
prior probability for the dataset. We prefer the least squares re-
gression because the underlying assumptions are more transparent.
Nonetheless, it is reassuring that least squares regression and or-
dered logistic regression gave the same ranking of the individual
in silico tools, and that the combination of MAPP + PolyPhen-2.1
emerged as the best pair using either forward selection or backward
selection with either regression method.
Finally, we specifically envision that the process of calibration
will be iterative. When a similarly sized independent series of mis-
sense substitutions have been classified qualitatively with reason-
able certainty (e.g., through the efforts of the InSiGHT Mutation
Interpretation Committee [Kohonen-Corish et al., 2011]), we will
analyze those variants using the models presented here for replica-
tion and refinement of the in silico missense prior probabilities of
pathogenicity. With the results of this work, all missense variants
can now be assigned a prior probability, using in silico tools. Thus,
any variants where another single source of reliable data exists (e.g.,
segregation, tumor histologic features) can now be assigned a poste-
rior probability, and thus lead to significant improvement in variant
classification.
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